PAA 2.63% 19.5¢ pharmaust limited

The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-850

  1. 3,261 Posts.
    lightbulb Created with Sketch. 475
    Great post @Quiltman
    One of the things I find so atrractive about PAA is the potential of MPL to encompass its own entire class of drug. It is the same reason I keep banging on about the importance of PAA staying independent and only doing licensing and/or JV's rather than accepting a short-sighted T/O
 
watchlist Created with Sketch. Add PAA (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.